Microport Robotics-B (02252) opened more than 8% due to profit in the morning, and the stock price quickly plunged and turned down after opening, falling more than 5% in the afternoon. As of the press time, it fell 4.91% to HK$8.53, with a turnover of 27.3172 million Hong Kong dollars.
According to Wisdom Finance App, Microport Robotics-B (02252) opened more than 8% due to profit in the morning, and the stock price quickly plunged and turned down after opening, falling more than 5% in the afternoon. As of the press time, it fell 4.91% to HK$8.53, with a turnover of 27.3172 million Hong Kong dollars.
In terms of news, Microport Robotics announced that the board of directors expects the company's revenue to increase by about 103% to 108% year-on-year by the end of June 2024. This growth is mainly due to the continuing strong sales momentum of the core product Titan Medical Laparoscopic Surgical Robot in the domestic market, the successful commercial installation overseas and the breakthrough in revenue. Honghu Bone Surgery Robot's overseas market share is gradually expanding; and the new product has contributed to the increase in income after its launch.
It is worth noting that Microport Robotics announced recently that it has signed a placement agreement with placement agents JPMorgan and China International Capital Corporation. In addition, Microport Robotics has recently carried out financing leases with its parent company, Microport Medical, which is essentially low-cost financial support provided by Microport Medical to Microport Robotics.
It is reported that in April this year, Microport Medical announced conditional relief from Hillhouse Capital. Under the agreement, Microport Medical needs to turn losses into profits within three years. A Nomura research report previously pointed out that the short-term situation of the company may improve, but long-term debt problems are still difficult.